Long-term safety of an implant delivering ranibizumab for wet macular degeneration

Trial details

Who runs it

Hoffmann-La Roche

Trial code

NCT03683251EU 2023-507131-38-00

Record updated

27 October 2026

Original description

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.Read full original descriptionShow less

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.

Inclusion: Previous enrollment in and completion of Study GX28228 (Ladder) or Study GR40548 (Archway), without early treatment or study discontinuation in either study OR Previous enrollment in Study WR42221 (Velodrome) and either not eligible to be randomized in Study WR42221 at Week 24 or completed the study (from the Q24W or Q36W arm); Ability and willingness to undertake all scheduled visits and assessments; For women of childbearing potential: agreement to remain abstinent or use contraceptive measures; For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures; Participants must meet the following ocular criteria for the study eye for substudy entry:; Diagnosis of exudative nAMD within 2 years prior to the enrollment visit; Previous treatment with at least two anti-VEGF ITV injections (e.g., ranibizumab, bevacizumab, or aflibercept) for nAMD per standard of care within 6 months prior to the enrollment visit; Demonstrated response to prior anti-VEGF ITV treatment since diagnosis, as evidenced at enrollment by the following:; Overall decrease in nAMD disease activity detected on SD-OCT AND Stable or improved best-corrected visual acuity (BCVA); All subtypes of nAMD lesions are permissible (i.e., type I, type II, type III, or mixed forms per optical coherence tomography (OCT) classification) nAMD lesions at the time of diagnosis must involve the macula (6 mm diameter centered at the fovea); Sufficiently clear ocular media and adequate pupillary dilation to allow for analysis and grading by the central reading center of FP and SD-OCT images; Having experienced septum dislodgement in the original implant while in the main study or after exiting the main study Ocular Inclusion Criteria for Study Eye; Sufficiently clear ocular media and adequate pupillary dilation to allow for analysis and grading by central reading center.

Exclusion: Pregnant or breastfeeding, or intending to become pregnant during the treatment period and for at least 28 days after the last intravitreal injection of ranibizumab or 1 year after the last Implant refill-exchange of ranibizumab; Requirement for continuous use of any medications or treatments indicated in the "Prohibited Therapy"; Sub-study 1; Prior treatment with Visudyne, external-beam radiation therapy, or transpupillary thermotherapy; Previous treatment with corticosteroid ITV injection; Previous intraocular device implantation; Previous laser (any type) used for AMD treatment; Either Eye; Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to the enrollment visit; Prior participation in a clinical trial involving anti-VEGF drugs within 6 months prior to the enrollment visit, other than ranibizumab; CNV Lesion Charateristics Study Eye; CNV due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia; Concurrent Ocular Conditions Study Eye; Any concurrent intraocular condition (e.g., cataract, glaucoma, diabetic retinopathy, or epiretinal membrane) that would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results; History of rhegmatogenous retinal tears or peripheral retinal breaks within 3 months prior to the enrollment visit; Previous violation of the posterior capsule is also an exclusion criterion unless it occurred as a result of yttrium-aluminum garnet (YAG) laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation; Preoperative refractive error that exceeds 8 diopters of myopia, for participants who have undergone prior refractive or cataract surgery in the study eye; Intraocular surgery (including cataract surgery) within 3 months preceding the enrollment visit; History of prior vitrectomy surgery and absence of posterior capsule; Either Eye; Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis; Concurrent Systemic Conditions; History of stroke within the last 3 months prior to informed consent; History of myocardial infarction within the last 3 months prior to informed consent; Chronic use of oral corticosteroids; Previous participation in any non-ocular (systemic) disease studies of investigational drugs within 1 month preceding the informed consent (excluding vitamins and minerals); Use of antimitotic or antimetabolite therapy within 30 days or 5 elimination half-lives of the enrollment visit; Pregnant or breastfeeding, or intending to become pregnant during the treatment period and for at least 28 days after the last ITV injection of ranibizumab or 1 year after the last implant refill-exchange of ranibizumab; Sub-study 2; Concurrent Ocular Conditions-Study Eye; Intraocular surgery (including cataract surgery) within 1 month preceding the enrollment visit; Any use of medicated intraocular implants (other than the PDS implant), at any time prior to enrollment; History of rhegmatogenous retinal tears or peripheral retinal breaks within 3 months prior to the enrollment visit; Any concurrent ocular condition that would require surgical intervention during the study to prevent or treat visual loss; Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero-temporal quadrant of the eye (e.g., scarring, thinning, mass) that may affect the refill-exchange procedure of the PDS implant; Ongoing ocular complications that might affect participant safety; Concurrent Ocular Conditions-Either Eye; Active blepharitis; Concurrent Systemic Conditions; Current systemic treatment for a confirmed active systemic infection - Participation in an investigational trial that involves treatment with any drug or device (with the exception of vitamins and minerals or enrollment in the main study GR40549) within 6 months prior to enrollment; Use of antimitotic or antimetabolite therapy within 30 days or 5 elimination half-lives; History of other ocular diseases that give reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab, that might affect interpretation of the results of the study or that renders the participant at high risk for treatment complications; History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD; Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage is greater than 0.5 disc area (1.27 mm2 ) in size at screening; History of vitreous hemorrhage; History of rhegmatogenous retinal detachment; Uncontrolled ocular hypertension or glaucoma and any such condition the investigator determines may require a glaucoma-filtering surgery during a patient's participation in the study; History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery; History of corneal transplant; History of idiopathic or autoimmune-associated uveitis; Current systemic treatment for a confirmed active systemic infection; Active cancer within 12 months of enrollment; History of albinism; Any ocular condition that may render the patient at high risk for surgical or treatment complications; Suspected or active ocular or periocular infection; Any history of uveitis; Active cancer within the last 12 months, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer; History of other diseases, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab or placement of the Implant and that might affect interpretation of the results of the study or that renders the participant at high risk of treatment complications; History of other disease, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab or placement of the implant and that might affect interpretation of the results of the study or renders the patient at high risk of treatment complications in the opinion of the investigator; Recent history (in the last 3 months prior to enrollment) of other disease, other non-diabetic metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of ranibizumab or surgical placement of the PDS implant; that might affect interpretation of the results of the study; or that renders the participant at high risk for treatment complications; Subfoveal fibrosis or subfoveal atrophy; Either Eye; Retinal pigment epithelial tear; Active intraocular inflammation (grade trace or above); Aphakia or absence of the posterior capsule; Spherical equivalent of the refractive error demonstrating more than 8 diopters of myopia; Inability to comply with study schedule or procedures as described in the study protocol; Uncontrolled blood pressure; Uncontrolled atrial fibrillation within 3 months of informed consent; Use of any systemic anti-VEGF agents.

ClinicalTrials.gov NCT03683251 · EU CTIS 2023-507131-38-00